Latest news

RM Partners held the first RAPID prostate pathway network meeting to share data, look at the similarities and differences of the three pilot pathways, and …

RM Partners has just launched a pilot in Sutton that uses an award winning AI decision support tool, C the Signs, to help GPs identify …

The second cancer biosimilar, trastuzumab, has been approved to treat patients with HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer. Biosimilar trastuzumab …

Clinicians from the three hospitals piloting the RM Partners RAPID prostate pathway attended an education day at Epsom Hospital that offered training in the use …

We are offering exciting opportunities for medical and non-medical research fellows to undertake a research project. This has London-based support from Biomedical Research Centres, RM …

RM Partners is holding a series of events in May to introduce healthcare professionals to the new operating model for six of our tumour-specific pathway …

RM Partners are offering an exciting opportunity for the appointment of a clinical lead to provide strategic and subject matter expert input into the RM …

The Daily Mail, along with The Times, the BBC and other news outlets, recently featured our new RAPID prostate cancer pathway that we are piloting …

  RM Partners is working alongside Kingston Council’s Public Health Department to increase participation in national cancer screening programmes across populations that are marginalised, do …

RM Partners runs a number of pathway groups assembled from healthcare professionals across west London that meet to share experience, best practice and innovation in …